You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,548,903


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,548,903
Title:Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
Abstract: Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, Alzheimer\'s disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Inventor(s): Labrie; Fernand (Quebec, CA), Gauthier; Sylvain (St-Augustin-de-Desmaures, CA)
Assignee: Endorecherche, Inc. (CA)
Application Number:15/626,774
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,548,903

Introduction

Understanding the intricacies of a specific patent, such as United States Patent 10,548,903, involves a deep dive into the claims, the broader patent landscape, and the regulatory framework that governs patent law in the United States. This analysis will cover the key aspects of patent law, the specific requirements for patentability, recent updates in patent guidance, and the implications of these factors on the patent in question.

Overview of U.S. Patent Law

The U.S. patent system is rooted in the Constitution, which grants Congress the authority to "promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries"[1].

Patent Administration and Requirements

The United States Patent and Trademark Office (USPTO) is responsible for issuing patents. For an invention to be patentable, it must meet several criteria:

  • Usefulness: The invention must be operable and provide some tangible benefit[1].
  • Novelty: The invention must not be fully anticipated by prior patents, publications, or other state of the art knowledge[1].
  • Nonobviousness: The invention must not have been readily within the ordinary skills of a competent artisan at the time it was made[1].
  • Patentable Subject Matter: The invention must fall within the categories of patentable subject matter as defined by statute and judicial interpretations[1].

The 2024 USPTO Guidance Update on AI Patents

Recent updates to USPTO guidance, particularly those related to AI and software patents, are crucial for understanding the patentability of modern inventions. The 2024 update clarifies several key points:

  • Abstract Ideas and Practical Applications: Claims must integrate judicial exceptions into practical applications to be considered patent-eligible. This involves assessing whether the claim imposes meaningful limits on the exception, transforming it into patent-eligible subject matter[2][5].
  • AI-Assisted Inventions: The method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[2].

Analyzing the Claims of United States Patent 10,548,903

To analyze the claims of this patent, one must consider the following:

Subject Matter Eligibility

Each claim must be evaluated to determine if it integrates abstract ideas into practical applications. For example, if a claim involves routine data processing without a specific practical application, it may be rejected under section 101 of the U.S. Code. However, if the claim specifies the use of the invention in a way that provides concrete benefits or solves specific problems, it is more likely to be considered patent-eligible[2][5].

Practical Applications

The claims should highlight real-world applications of the method or system. Demonstrating how the abstract idea is applied in a way that provides tangible benefits or solves specific problems is crucial. For instance, if the patent involves AI-related claims, specifying the use of AI in a real-time speech recognition system to enhance accuracy would make the claim more likely to be patent-eligible[2].

Nonobviousness and Novelty

The claims must also be evaluated for nonobviousness and novelty. This involves comparing the invention to prior art and ensuring that it does not merely combine existing elements in an obvious way. The USPTO examiner will consider whether the invention would have been readily apparent to a competent artisan at the time it was made[1].

Implications of Recent Case Law and Guidance

Recent case law and the 2024 USPTO guidance update provide significant insights into how claims should be crafted and evaluated. For AI inventions, the focus on practical applicability and concrete technological advancements is paramount. This means that claims must go beyond mere abstract ideas and demonstrate meaningful limits and practical applications[2][5].

Gender and Diversity in Patenting

While analyzing the patent landscape, it is also important to consider broader trends, such as the gender patenting gap. Women hold a very small share of patents, and at the current rate, gender patent equity is more than 75 years away[4]. This gap highlights the need for greater diversity and inclusion in innovation and patenting.

Patent Litigation and Data

Understanding the patent litigation landscape can also provide context. The USPTO's Patent Litigation Docket Report Data offers comprehensive insights into patent litigation trends, including the types of cases, litigating parties, and outcomes. This data can help in assessing the potential risks and challenges associated with enforcing a patent[3].

Key Takeaways

  • Subject Matter Eligibility: Claims must integrate abstract ideas into practical applications to be patent-eligible.
  • Practical Applications: Highlighting real-world applications and tangible benefits is crucial for overcoming section 101 rejections.
  • AI-Assisted Inventions: AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution.
  • Nonobviousness and Novelty: Claims must be novel and nonobvious compared to prior art.
  • Diversity in Patenting: The gender patenting gap highlights the need for greater diversity in innovation.

FAQs

Q: What are the main criteria for an invention to be patentable in the United States? A: An invention must be useful, novel, nonobvious, and fall within the categories of patentable subject matter.

Q: How does the 2024 USPTO guidance update affect AI-related patent claims? A: The update emphasizes the importance of integrating abstract ideas into practical applications and ensures that AI-assisted inventions are evaluated on equal footing with other technologies.

Q: What is the significance of practical applications in patent claims? A: Practical applications are crucial for demonstrating that a claim offers concrete technological improvements and provides tangible benefits, making it more likely to be patent-eligible.

Q: How does the gender patenting gap impact innovation? A: The gender patenting gap highlights the need for greater diversity and inclusion in innovation, as women hold a very small share of patents.

Q: What resources are available for analyzing patent litigation trends? A: The USPTO's Patent Litigation Docket Report Data provides comprehensive insights into patent litigation trends, including case types, litigating parties, and outcomes.

Sources

  1. Congressional Research Service. Patents and Innovation Policy, August 2022.
  2. Mintz. Understanding the 2024 USPTO Guidance Update on AI Patent, July 2024.
  3. USPTO. Working papers and book chapters, March 2024.
  4. Institute for Women's Policy Research. The Gender Patenting Gap, December 2020.
  5. Baker Botts. The Importance of Prong Two of Step 2A for AI Inventions, September 2024.

More… ↓

⤷  Subscribe

Details for Patent 10,548,903

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 ⤷  Subscribe 2034-03-10
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 ⤷  Subscribe 2034-03-10
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 ⤷  Subscribe 2034-03-10
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 16, 1990 ⤷  Subscribe 2034-03-10
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 March 26, 1974 ⤷  Subscribe 2034-03-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.